Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate

Viking Therapeutics (VKTX) stock crashed over 40% after its oral weight-loss drug, VK2735, reported a 28% patient dropout rate in Phase 2 trials over just 13 weeks, largely due to gastrointestinal side effects, despite achieving a 12.2% mean weight loss. Analysts deemed this data inferior to Eli Lilly's (LLY) competing oral treatment, which saw a 25% dropout rate over a much longer 72-week Phase 3 trial, consequently boosting Eli Lilly and Novo Nordisk (NVO) shares as the competitive landscape for oral obesity treatments intensifies.

Analysis

Viking Therapeutics (VKTX) stock collapsed by over 40% following the release of its Phase 2 trial data for the oral weight-loss drug VK2735. The severe market reaction was driven primarily by a poor tolerability profile, which overshadowed the drug's efficacy. While patients achieved a notable 12.2% body weight loss in just 13 weeks, an alarmingly high 28% of participants discontinued the treatment during this short period due to adverse gastrointestinal events, including a 58% incidence of nausea. This data compares unfavorably with results from competitor Eli Lilly's (LLY) oral drug, orforglipron, which reported a similar 25% dropout rate but over a much longer 72-week Phase 3 trial. As highlighted by Mizuho analysts, this stark difference in trial duration makes LLY's candidate appear significantly superior in a head-to-head comparison. The market has interpreted Viking's setback as a competitive win for established players, reflected by the 1.7% rise in LLY shares and a greater than 1% increase for Novo Nordisk (NVO), suggesting investors see this as a de-risking event for the market leaders.

Key Decisions for Investors

• Investors should treat the high 28% patient dropout rate over a short 13-week period as a significant red flag for Viking's VK2735, as it questions the drug's commercial viability and long-term tolerability.
• The market's positive reaction for Eli Lilly and Novo Nordisk suggests Viking's stumble strengthens their competitive position, potentially reinforcing the investment thesis for holding or accumulating positions in these established obesity market leaders.
• Tolerability and discontinuation rates, not just efficacy, are emerging as critical differentiating factors in the oral obesity drug race; these metrics should be prioritized when evaluating competing assets in the sector.